A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

NCT02935686 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: Ad26.Mos4.HIV
BIOLOGICAL: Clade C gp140 plus adjuvant
BIOLOGICAL: Clade C gp140/Mosaic gp140 plus adjuvant
OTHER: Placebo
BIOLOGICAL: gp140 HIV Bivalent Vaccine

Sponsor

Janssen Vaccines & Prevention B.V.